Publication | Closed Access

Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats

Metabolic SyndromeInsulin SignalingMedicineDiabetesPhysiologyDiabetic Kidney DiseaseDiabetes MellitusDiabetic CardiomyopathyPharmacologyStreptozotocin-induced Diabetic RatsCell SignalingAkt/jak/mapk PathwaysOxidative StressHealth Sciences